References
- Aaron, E., Kempf, M.-C., Criniti, S., Tedaldi, E., Gracely, E., Warriner, A., … Bachmann, L. H. (2010). Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication. PLoS One, 5(9), e12617. doi:10.1371/journal.pone.0012617.t004
- Bera, E., & Mia, R. (2012). Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: A systematic review and meta-analysis. South African Medical Journal, 11, 855–859. doi:10.7196/SAMJ.5700
- Kea, C., Puthanakit, T., Apornpong, T., Lumbiganon. P., Ung, V., Hansudewechakul R., … Ruxrungtham K. (2013). Incidence and risk factors for nevirapine related toxicities among HIV-infected Asian children randomized to starting ART at different CD4%. Paper presented at 6th IAS Conference on HIV Pathogenesis and Treatment. Retrieved from http://www.iasociety.org/Abstracts/A200743049.aspx
- Kondo, W., Carraro, E. A., Prandel, E., Dias, J. M., Perini, J., Macedo, R. L., … Sasaki, M. G. (2007). Nevirapine-induced side-effects in pregnant women – Experience of a Brazilian University hospital. Brazilian Journal of Infectious Diseases, 11, 544–548. Retrieved from www.bjid.com.br. doi:10.1590/S1413-86702007000600004
- Kumarasamy, N., Venkatesh, K. K., Devaleenal, B., Palanivel, V., Cecelia, A. J., Muthu, S., … Flanigan, T. (2007). Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting. Journal of Acquired Immune Deficiency Syndrome, 45, 598–600. doi:10.1097/QAI.0b013e318074ef99
- Marazzi, M. C., Germano, P., Liotta, G., Guidotti, G., Loureiro, S., da Cruz Gomes A., … Palombi, L. (2006). Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Medicine, 7, 338–344. doi:10.1111/j.1468-1293.2006.00386.x
- National AIDS Control Organization. (2006). Guidelines on HIV care and treatment in infants and children; Anti-retroviral treatment in infants and children. New Delhi: Ministry of Health and Family Welfare.
- Ouyang, D. W., Brogly, S. B., Lu, M., Shapiro, D. E., Hershow, R. C., French, A. L., … Tuomala, R. E. (2010). Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals. AIDS, 24(1), 109–114. doi:10.1097/QAD.0b013e3283323941
- Theo, S., & Keith, A. (2009). Switching from efavirenz to nevirapine in women with higher CD4 counts. HATiP, 136: 1–9. Retrieved from http://www.aidsmap.com/pdf/HATIP-136-7th-May-2009/page/1321567/
- US Food and Drug Administration Center for Drug Evaluation and Research. (2005, January 19). FDA public health advisory for nevirapine (Viramune™). Efficacy and safety concerns regarding the coadministration of tenofovir disoproxil fumarate (TDF, Viread) and didanosine (ddI, Videx). EMEA Public Statement (EMEA/6231/2005). Retrieved from http://www.fda.gov/cder/drug/advisory/nevirapine.htm
- World Health Organization. (2013, June). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva: Author. Retrieved from http://www.who.int/hiv/pub/guidelines/arv2013/en/
- Wit, F. W. N. M., Kesselring, A. M., Gras, L., Richter, C., van der Ende, M. E., Brinkman, K., … Reiss, P. (2008). Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment- naive patients: The ATHENA cohort study. Clinical Infectious Disease, 46, 933–940. doi:10.1086/528861
![Supercharge Your Next Research Paper: Research and write your next paper with Jenni AI.]({"type":"image" , "src" : "/sda/112443/Skyscraper-socialsciences.png"})